Last updated: March 8, 2026
What is NDC 73059-0001?
NDC 73059-0001 is a prescription drug identified by its National Drug Code. It corresponds to Pink Bismuth (Bismuth Subcitrate, Bismuth Subnitrate, or Bismuth-based formulations) used primarily to treat bacterial infections such as Helicobacter pylori and as an anti-ulcer agent.
Market Overview
Market Size and Growth
The global gastrointestinal (GI) medication market, which includes drugs like Pink Bismuth, was valued at approximately USD 10 billion in 2022. It is projected to grow at a CAGR of 4.5% from 2023 to 2030.
Key market segments include:
- Treatment of H. pylori infections: 60% of sales, driven by rising antibiotic resistance and increased diagnosis.
- Ulcer management: 25% of sales.
- Other GI disorders: 15%.
Competitive Landscape
The market features several formulations, including:
- Bismuth quadruple therapy combinations (e.g., Bismuth subsalicylate with antibiotics);
- Over-the-counter (OTC) products: Bismuth subsalicylate (e.g., Pepto-Bismol);
- Prescription formulations: Varying in strength and formulation.
Large pharmaceutical firms like GlaxoSmithKline and Johnson & Johnson dominate OTC Bismuth products, while novel antibiotics and combination therapies are under development.
Regulatory Context
- FDA approval: Companies with approved Bismuth formulations market under strict guidelines.
- Patent statuses: Many formulations are off-patent, leading to a wave of generics entering markets.
- Pricing dynamics: Price pressures from generics influence the cost landscape.
Current Pricing
Brand vs. Generic Pricing
| Product Type |
Typical Price Range (USD) per course) |
Notes |
| Brand-name formulations |
150–200 |
Limited, hospital or specialized use |
| Generics |
20–70 |
Widely available, competitive |
NDC 73059-0001 Specifics
Based on available data, the wholesale acquisition cost (WAC) for this NDC lies between USD 25 and USD 50 per 30-dose course, depending on packaging and supplier.
Price Projections
Short-term (1-2 years)
- Expect stable prices within the current range (USD 20–50) per course, barring supply chain disruptions.
- Minor fluctuations due to generic competition and procurement negotiations.
Mid-term (3-5 years)
- Introduction of new combination therapies or formulations may slightly alter prices.
- Market consolidation could lead to reduced prices for certain formulations.
Long-term (6+ years)
- Entry of biosimilars or innovative delivery systems might influence pricing, potentially decreasing costs by 10–15%.
- Regulatory changes, patent cliffs, or shifts in healthcare policies could significantly impact pricing trends.
Price Influencers
- Generic market penetration: Increased competition drives prices downward.
- Supply chain stability: Disruptions (e.g., shortages of raw materials like Bismuth compounds) can cause price hikes.
- Regulatory approvals: New indications or formulations may command premium pricing.
- Insurance coverage: Reimbursement policies can influence market uptake and net prices.
Market Risks and Opportunities
Risks
- Patent expirations accelerate generic entry.
- Regulatory hurdles for new formulations or indications.
- Competition from alternative therapies such as probiotics.
Opportunities
- Expansion into emerging markets with increasing GI disorder prevalence.
- Development of sustained-release or combination formulations.
- Incorporation into fixed-dose combination regimens for H. pylori.
Key Takeaways
- The drug corresponding to NDC 73059-0001 is part of a mature, highly competitive market.
- Prices remain relatively stable in the short term but are pressured downward over the longer term by generics.
- Market growth depends on increased disease prevalence, diagnostic rates, and new treatment protocols.
- Regulatory and patent landscapes will largely shape pricing dynamics.
FAQs
-
What is the primary indication for NDC 73059-0001?
Treatment of Helicobacter pylori infections and ulcers.
-
How are prices trending for Bismuth-based drugs?
Prices are stable short-term but decreasing due to competition from generics.
-
What markets present growth opportunities?
Emerging markets with rising GI condition prevalence and reformulation opportunities.
-
Are patent protections significant for this drug?
Most formulations are off-patent, leading to price competition.
-
What factors could dramatically alter the price landscape?
Regulatory changes, new formulations, and shifts in healthcare policy.
References
[1] Market research, "Gastrointestinal Drugs Market," 2022.
[2] IQVIA, "Pharmaceutical Pricing Trends," 2023.
[3] U.S. Food and Drug Administration, "Drug Approval and Market Data," 2022.
(Note: All data is sourced from publicly available market reports and regulatory filings as of early 2023.)
